Citizens Upgrades Apyx Medical to Market Outperform, Announces $8 Price Target
Benzinga Newsdesk 11 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Citizens analyst David Turkaly upgrades Apyx Medical (NASDAQ:APYX) from Market Perform to Market Outperform and announces $8 price target.
Citizens analyst David Turkaly upgrades Apyx Medical (NASDAQ:APYX) from Market Perform to Market Outperform and announces $8 price target.